Reduced-intensity chemotherapy with tyrosine kinase inhibitor followed by allogeneic transplantation is effective in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
When imatinib plus reduced-intensity therapy was used as a frontline treatment, there was no inferiority in obtaining complete remission compared to imatinib plus intensive chemotherapy or significant difference in long-term survival. Since imatinib plus reduced-intensity therapy has limitations in obtaining a deep molecular response, proceeding to allo-SCT should be considered.
Authors
- Young Rok (ORCID: https://orcid.org/0000-0003-1631-1359)
- Joon Ho Moon (ORCID: https://orcid.org/0000-0003-3756-796X)
- Mi Hwa Heo (ORCID: https://orcid.org/0000-0003-3997-8463)
- Hee Jeong Cho (ORCID: https://orcid.org/0000-0001-8300-8179)
- Dong Won Baek (ORCID: https://orcid.org/0000-0003-4446-1549)
- Do Young Kim (ORCID: https://orcid.org/0000-0002-8327-3439)
- Jung Min Lee (ORCID: https://orcid.org/0000-0002-8033-0725)
- Min Kyoung Kim (ORCID: https://orcid.org/0000-0003-0477-2588)
- Ho Jin Shin
- Sang Kyun Sohn
- Young Seob Park
Institutions
- Kyungpook National University Hospital (KR)
- Pusan National University Hospital (KR)
- Keimyung University Dongsan Medical Center (KR)
- Yeungnam University Medical Center (KR)
- Yeungnam University College
- Keimyung University (KR)
Publication Details
- Journal
- The Korean Journal of Internal Medicine
- Published
- 2024-12-31
- DOI
- https://doi.org/10.3904/kjim.2024.227
- Primary Topic
- Chronic Myeloid Leukemia Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00